Pulse Biosciences/$PLSE
Pulse Biosciences stock jumps after Freedom Capital initiated coverage with a Buy rating and $73 target, highlighting its nsPFA technology’s potential in the atrial fibrillation ablation market and strong cash runway.
9 hours agoLightyear AI
1D1W1MYTD1Y5YMAX
Capital at risk
About Pulse Biosciences
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to nonthermally clear cells while sparing adjacent noncellular tissue.
- Ticker
- $PLSE
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 116
- Headquarters
- Miami, United States
- Website
- www.pulsebiosciences.com
PLSE Metrics
BasicAdvanced
$3.5B
-
-$1.18
1.58
-
Price and volume
Market cap
$3.5B
Beta
1.58
52-week high
$55.37
52-week low
$12.56
Average daily volume
503K
Financial strength
Current ratio
9.628
Quick ratio
9.268
Long term debt to equity
5.112
Total debt to equity
6.806
Profitability
EBITDA (TTM)
-82.618
Gross margin (TTM)
0.25%
Net profit margin (TTM)
-6,755.78%
Operating margin (TTM)
-7,058.40%
Revenue per employee (TTM)
$10,000
Management effectiveness
Return on assets (TTM)
-44.34%
Return on equity (TTM)
-78.49%
Valuation
Price to revenue (TTM)
2,803.701
Price to book
34.72
Price to tangible book (TTM)
35.8
Price to free cash flow (TTM)
-54.121
Free cash flow yield (TTM)
-1.85%
Free cash flow per share (TTM)
-0.902
Growth
Earnings per share change (TTM)
9.61%
3-year revenue growth (CAGR)
408.74%
3-year earnings per share growth (CAGR)
-0.08%
10-year earnings per share growth (CAGR)
5.28%
What the Analysts think about PLSE
Analyst ratings (Buy, Hold, Sell) for Pulse Biosciences stock.
Analyst projections of the future price of Pulse Biosciences stock.
Bulls say / Bears say
NANOPULSE-AF enrollment momentum improved: Pulse surpassed the midpoint of its pivotal U.S. atrial-fibrillation study, exceeded 82 evaluable patients, and maintained a target to complete enrollment in early Q4 2026 even after increasing the evaluable-patient target by 19. (Pulse Biosciences)
The platform is showing promising operational characteristics in early cardiac use, with multiple sites performing at least five cases per day and several physicians achieving ablation times of 7–8 minutes or less within their first cases. (Pulse Biosciences)
Liquidity strengthened materially: cash and equivalents reached $101.6 million at June 30, 2026, up from $68.3 million at March 31, while insider and external ATM participation provided funding for upcoming clinical and regulatory milestones. (Pulse Biosciences)
Commercial traction remains minimal: Q2 2026 revenue was only $0.4 million, while GAAP expenses rose to $25.7 million and quarterly net loss widened to $24.7 million. (Pulse Biosciences)
Continued financing needs create dilution risk: Pulse raised $46.8 million through its ATM in Q2, issued additional shares, and established a new $75 million ATM alongside an available $125 million shelf. (Pulse Biosciences)
The core cardiac opportunity remains dependent on pivotal-trial and regulatory execution; the company warns that early feasibility results may not predict expanded-trial outcomes, and FDA or other approvals may be delayed or denied. (SEC Form 10-Q)
Data summarised monthly by Lightyear AI. Last updated on 9 Sept 2026.
PLSE Financial Performance
Revenues and expenses
PLSE Earnings Performance
Company profitability
Upcoming events
No upcoming events
PLSE News
AllArticlesVideos
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire6 days ago
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire3 weeks ago
Pulse Biosciences Eyes AFib Breakthrough With Nanosecond PFA Platform
MarketBeat3 weeks ago
Funds containing PLSE
AllEURGBP
Fund name | Fund size | $PLSE weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.04% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.02% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | £2.4B | 0.02% |
SPDR MSCI All Country World IM€SPYI | €7.5B | 0.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.